文献速递头颈胸部技术与安全US

肺癌转移性淋巴结的超声造影灌注模式与时间-强度曲线分析:初步结果

Analysis of Contrast-Enhanced Ultrasound Perfusion Patterns and Time-Intensity Curves for Metastatic Lymph Nodes From Lung Cancer: Preliminary Results.
PubMed 文献 · J Ultrasound Med · 2017-09-06

回顾性纳入61例经组织学确诊的肺癌锁骨上转移性淋巴结患者,分析不同病理类型(鳞癌26例、腺癌26例、小细胞癌9例)的超声造影灌注模式与时间-强度曲线参数,并评估微血管密度与微血管直径。结果显示三种病理类型在动脉期增强均匀性及无增强区存在方面无显著差异(P > .05),但腺癌转移淋巴结无增强区较少;鳞癌与腺癌转移淋巴结的峰值强度有显著差异(P < .05);腺癌转移淋巴结微血管密度显著高于鳞癌(P < .001)和小细胞癌(P = .0444),微血管直径显著小于鳞癌(P = .0277)和小细胞癌(P < .001)。

要点

  • 肺癌锁骨上转移性淋巴结超声造影动脉期增强均匀性和无增强区存在在三种病理类型间无显著差异(P > .05)。
  • 腺癌转移淋巴结无增强区较少见,峰值强度与鳞癌转移淋巴结有显著差异(P < .05)。
  • 腺癌转移淋巴结微血管密度高于鳞癌(P < .001)和小细胞癌(P = .0444),微血管直径小于鳞癌(P = .0277)和小细胞癌(P < .001)。

核心结论

  • 分析转移性淋巴结超声造影定量参数时应考虑病理诊断的影响,即使位于同一器官。

研究设计与样本

  • 回顾性研究,纳入61例经组织学确诊的肺癌锁骨上淋巴结转移患者,其中鳞癌26例、腺癌26例、小细胞癌9例,分析超声造影灌注模式和时间-强度曲线参数,并评估微血管密度和微血管直径。

关键影像表现/征象

  • 三种病理类型转移性淋巴结在动脉期增强均匀性及无增强区存在方面无显著差异(P > .05)。
  • 腺癌转移淋巴结无增强区较少见。
  • 鳞癌与腺癌转移淋巴结的峰值强度有显著差异(P < .05)。

诊断标准与关键数值

  • 鳞癌与腺癌转移性淋巴结峰值强度差异有统计学意义(P < .05)。
  • 腺癌转移淋巴结微血管密度显著高于鳞癌(P < .001)和小细胞癌(P = .0444)。
  • 腺癌转移淋巴结微血管直径显著小于鳞癌(P = .0277)和小细胞癌(P < .001)。

临床应用与阅片要点

  • 分析肺癌转移性淋巴结超声造影时间-强度曲线定量参数时,应考虑原发肿瘤病理类型的影响。
  • 动脉期增强均匀性和无增强区存在在三种病理类型间无显著差异,腺癌转移淋巴结无增强区较少见。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: To retrospectively summarize the similarities and differences in contrast-enhanced ultrasound (US) findings for lymph node metastasis from adenocarcinoma, squamous carcinoma, and small cell lung cancer.

METHODS: Patients who had received contrast-enhanced US examinations and had a histologic diagnosis of supraclavicular lymph node metastasis from lung cancer were included. The perfusion patterns on contrast-enhanced US images and time-intensity curve parameters were analyzed for the different pathologic types. The microvascular density and microvascular diameter were evaluated.

RESULTS: Totally, 61 patients were enrolled in this study, including 26 cases with lung squamous carcinoma, 26 with lung adenocarcinoma, and 9 with small cell lung cancer. Contrast-enhanced US perfusion showed no significant differences in enhancement uniformity during the arterial phase and in the presence of unenhanced areas of metastatic lymph nodes with the 3 different pathologic origins (P > .05), but fewer unenhanced areas could be seen in metastatic lymph nodes from adenocarcinoma. The analysis of the time-intensity curve parameters showed that there were significant differences in the peak intensity between metastatic lymph nodes from lung squamous carcinoma and lung adenocarcinoma (P < .05). The microvascular density of metastatic lymph nodes from adenocarcinoma was significantly higher than that of metastatic lymph nodes from squamous carcinoma and small cell lung cancer (P < .001; P = .0444), whereas the microvascular diameter of metastatic lymph nodes from adenocarcinoma was significantly smaller than that from squamous carcinoma and small cell lung cancer (P = .0277; P < .001).

CONCLUSIONS: Effects of the pathologic diagnosis should be considered when analyzing quantitative parameters of metastatic lymph nodes during contrast-enhanced US examinations, even in the same organ.

来源:J Ultrasound Med,查看原文。版权归原作者所有。

引用

  1. Yin S, Cui Q, Wang S, et al. Analysis of Contrast-Enhanced Ultrasound Perfusion Patterns and Time-Intensity Curves for Metastatic Lymph Nodes From Lung Cancer: Preliminary Results. J Ultrasound Med. 2017. PMID: 28877356. doi:10.1002/jum.14345

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。